Clinical Trials
Study Title:
The CompassHER2 Trials (Comprehensive Use of Pathological Response Assessment to Optimize Therapy in HER2 Positive Breast Cancer): CompassHer2 Residual Disease (RD), A Double Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
|
For more information about the trial above please contact the study team:
Lexington Medical Center
Affiliate Principal Investigator, Steven Madden, at samadden@lexhealth.org.
Study Coordinator, Katherine Madden, at kdmadden@lexhealth.org.
Medical University of South Carolina
Principal Investigator, Frank Brescia, at bresciaf@musc.edu.
Study Coordinator, Margaret (Maggie) Scott, at scotmarg@musc.edu.
Tidelands Health
Affiliate Principal Investigator, Sara Adams, at baadamssr@gmail.com.
Study Coordinator, Barbara Roe, at broe@tidelandshealth.org.
Trial opened at the following institutions: Beaufort Memorial Hospital - SC, Lexington Medical Center, Medical University of South Carolina, Tidelands Health |